Combination of PI3K/Akt/mTOR inhibitors and PDT in endothelial and tumor cells

Progress in Biomedical Optics and Imaging - Proceedings of SPIE

Volumn 7886, Issue , 2011, Pages

  Fateye, Babasola ^a   Chen, Bin ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

BEZ235; LY294002; PI3K Akt mTOR; Prostate Cancer; Vascular targeting Photodynamic Therapy; Verteporfin

Indexed keywords

ANTIBIOTICS; CELL CULTURE; CELL DEATH; DISEASES; ENDOTHELIAL CELLS; ENZYME INHIBITION; PHOTODYNAMIC THERAPY; SIGNALING; TUMORS; UROLOGY;

BEZ235; LY294002; PI3K/AKT/ MTOR; PROSTATE CANCERS; VERTEPORFIN;

CELL SIGNALING;

EID: 79954562384     PISSN: 16057422     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1117/12.876042     Document Type: Conference Paper

References (37)

1. Castano, A.P., T.N. Demidova, and M.R. Hamblin, Mechanisms in photodynamic therapy: part two - cellular signaling, cell metabolism and modes of cell death. Photodiagnosis and Photodynamic Therapy, 2005. 2(1): p. 1-23.
2. Chen, B., et al., Vascular and Cellular Targeting for Photodynamic Therapy. 2006. 16(4): p. 279-306.
3. Lepor, H., Vascular targeted photodynamic therapy for localized prostate cancer. Reviews in Urology, 2008. 10(4): p. 254-61.
4. Engelman, J.A., Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer, 2009. 9(8): p. 550-562.
5. Hennessy, B.T., et al., Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery. Nat Rev Drug Discov, 2005. 4(12): p. 988-1004.
6. Knight, Z.A., H. Lin, and K.M. Shokat, Targeting the cancer kinome through polypharmacology. Nat Rev Cancer, 2010. 10(2): p. 130-137.
7. Kong, D., et al., Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. European journal of cancer (Oxford, England : 1990), 2010. 46(6): p. 1111-1121.
8. Almeida, R.D., et al., Intracellular signaling mechanisms in photodynamic therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2004. 1704(2): p. 59-86.
9. Markman, B., et al., Status of PI3K inhibition and biomarker development in cancer therapeutics. Annals of Oncology, 2009.
10. Bunney, T.D. and M. Katan, Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer, 2010. 10(5): p. 342-352.
11. Li, L., et al., The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis, 2005. 8(2): p. 108-118.
12. Liu, P., et al., Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov, 2009. 8(8): p. 627-644.
13. Dormond, O., J.C. Madsen, and D.M. Briscoe, The Effects of mTOR-Akt Interactions on Anti-apoptotic Signaling in Vascular Endothelial Cells. Journal of Biological Chemistry, 2007. 282(32): p. 23679-23686.
14. Phung, T.L., et al., Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer cell, 2006. 10(2): p. 159-170.
15. Le Page, C., et al., Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. British Journal of Cancer, 2006. 94: p. 1906-1912.
16. Neufeld, T.P., TOR-dependent control of autophagy: biting the hand that feeds. Current Opinion in Cell Biology, 2010. 22(2): p. 157-168.
17. Isaacs, W.B., B.S. Carter, and C.M. Ewing, Wild-Type p53 Suppresses Growth of Human Prostate Cancer Cells Containing Mutant p53 Alleles. Cancer Res, 1991. 51(17): p. 4716-4720.
18. Ravikumar, B., et al., Mammalian macroautophagy at a glance. J Cell Sci, 2009. 122(11): p. 1707-1711.
19. Sharrard, R.M. and N.J. Maitland, Regulation of Protein Kinase B activity by PTEN and SHIP2 in human prostate-derived cell lines. Cellular Signalling, 2007. 19(1): p. 129-138.
20. Ross, A.H. and A. Gericke, Phosphorylation keeps PTEN phosphatase closed for business. Proceedings of the National Academy of Sciences, 2009. 106(5): p. 1297-1298.
21. Clerkin, J.S., et al., Mechanisms of ROS modulated cell survival during carcinogenesis. Cancer Letters, 2008. 266(1): p. 30-36.
22. Yu, S., et al., Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Molecular Cancer Therapeutics, 2008. 7(9): p. 2609-2620.
23. Vlahos, C.J., et al., A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). Journal of Biological Chemistry, 1994. 269(7): p. 5241-5248.
24. Ballou, L.M., et al., Inhibition of Mammalian Target of Rapamycin Signaling by 2-(Morpholin-1-yl)pyrimido[2,1-α]isoquinolin-4-one. Journal of Biological Chemistry, 2007. 282(33): p. 24463-24470.
25. Domin, J., Pages, J., Volinia, S., Rittenhouse, S.E., Zvelebil, M.J., Stein, R.C., Waterfield, M.D., Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochemical Journal, 1997. 326: p. 139-147.
26. Brunn, G.J., Williams, J., Sabers, C., Wiederrecht, G., Lawrence, J.C. and Abraham, R.T., Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO, 1996. 15(19): p. 5256-5267.
27. Gharbi, S.I., et al., Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J, 2007. 404(1): p. 15-21.
28. Chaussade, C., et al., Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J, 2007. 404(3): p. 449-458.
29. Maira, S.-M., et al., Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular Cancer Therapeutics, 2008. 7(7): p. 1851-1863.
30. Chen, B., et al., Disparity between prostate tumor interior versus peripheral vasculature in response to verteporfin-mediated vascular-targeting therapy. International Journal of Cancer, 2008. 123(3): p. 695-701.
31. Byrne, A.T., et al., Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment. Br J Cancer, 2009. 101(9): p. 1565-1573.
32. Poh, T.W. and Pervaiz, S.. LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway. Cancer Research 2005; 65(14): 6264-74.
33. Allison, R.R. and C.H. Sibata, Oncologic photodynamic therapy photosensitizers: A clinical review. Photodiagnosis and Photodynamic Therapy, 2010. 7(2): p. 61-75.
34. Dewaele, M., et al., Autophagy pathways activated in response to PDT contribute to cell resistance against ROS damage. Journal of Cellular and Molecular Medicine, 2010.
35. Kessel, D., M.G.H. VIncente, and J.J. Reniners, Initiation of apoptosis and autophagy by photodynamic therapy. Lasers in Surgery and Medicine, 2006. 38(5): p. 482-488.
36. Weyergang, A., et al., Photodynamic Therapy Targets the mTOR Signaling Network in Vitro and in Vivo. Molecular Pharmaceutics, 2008. 6(1): p. 255-264.
37. Wu, Y.-T., et al., Activation of the PI3K-Akt-mTOR signaling pathway promotes necrotic cell death via suppression of autophagy. Autophagy, 2009. 5(6): p. 824-834.